Cargando…

Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel

Mostrar otras versiones (1)

The individual-level effectiveness of vaccines against clinical disease caused by SARS-CoV-2 is well-established. However, few studies have directly examined the effect of COVID-19 vaccines on transmission. We quantified the effectiveness of vaccination with BNT162b2 (Pfizer-BioNTech mRNA-based vacc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prunas, Ottavia, Warren, Joshua L., Crawford, Forrest W., Gazit, Sivan, Patalon, Tal, Weinberger, Daniel M., Pitzer, Virginia E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722617/ https://www.ncbi.nlm.nih.gov/pubmed/34981074 http://dx.doi.org/10.1101/2021.07.13.21260393

Ejemplares similares

Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
por: Prunas, Ottavia, et al.
Publicado: (2022)

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
por: Prunas, Ottavia, et al.
Publicado: (2022)

Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study
por: Gazit, Sivan, et al.
Publicado: (2022)

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
por: Patalon, Tal, et al.
Publicado: (2022)

Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study
por: Yechezkel, Matan, et al.
Publicado: (2023)

Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization
por: Chodick, Gabriel, et al.
Publicado: (2021)

Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
por: Mofaz, Merav, et al.
Publicado: (2022)

Mpox Patient Journey in Israel
por: Patalon, Tal, et al.
Publicado: (2023)

BNT162b2 mRNA COVID-19 Vaccine Effectiveness in Patients with Coeliac Disease Autoimmunity: Real-World Data from Mass Vaccination Campaign
por: Ben-Tov, Amir, et al.
Publicado: (2023)

Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
por: Grupel, Daniel, et al.
Publicado: (2021)

Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation
por: Gazit, Sivan, et al.
Publicado: (2023)

A Data-Driven Strategy for Identifying Individuals Resistant to SARS-CoV-2 Virus under In-Household Exposure
por: Hen Gabzi, Roni, et al.
Publicado: (2022)

An Outbreak of Parvovirus B19 in Israel
por: Patalon, Tal, et al.
Publicado: (2023)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Immunosuppression as a Hub for SARS-CoV-2 Mutational Drift
por: Shapira, Guy, et al.
Publicado: (2023)

Incorporating data from multiple endpoints in the analysis of clinical trials: example from RSV vaccines
por: Prunas, Ottavia, et al.
Publicado: (2023)

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel
por: Brosh-Nissimov, Tal, et al.
Publicado: (2021)

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2022)

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
por: Mevorach, Dror, et al.
Publicado: (2021)

Impact of BNT162b2 Vaccination and Isolation on SARS-CoV-2 Transmission in Israeli Households: An Observational Study
por: Layan, Maylis, et al.
Publicado: (2022)

Transplacental transfer of SARS-CoV-2 antibodies in recovered and BNT162b2-vaccinated patients
por: Treger, Sharon, et al.
Publicado: (2022)

SARS-CoV-2 spike IgG titres up to 137 days following Comirnaty mRNA COVID-19 vaccination, Israel, February to May 2021
por: Patalon, Tal, et al.
Publicado: (2022)

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
por: Regev-Yochay, Gili, et al.
Publicado: (2021)

P652: IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BETWEEN 1998-2022, INCLUDING THE ERA OF TARGET THERAPIES WITH BCL2 AND BTK INHIBITORS.
por: Tadmor, Tamar, et al.
Publicado: (2023)

Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents
por: Patalon, Tal, et al.
Publicado: (2023)

Mpox Infection in a Developed Country: A Case Report
por: Patalon, Tal, et al.
Publicado: (2022)

Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel
por: Muhsen, Khitam, et al.
Publicado: (2021)

BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign
por: Ben-Tov, Amir, et al.
Publicado: (2021)

CORRECTION TO: IMPACT OF BNT162B2 VACCINATION AND ISOLATION ON SARS-COV-2 TRANSMISSION IN ISRAELI HOUSEHOLDS: AN OBSERVATIONAL STUDY
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel
por: Glatman-Freedman, Aharona, et al.
Publicado: (2022)

Pregnancy Course of 10 Women Diagnosed with Chronic Lymphocytic Leukemia
por: Tadmor, Tamar, et al.
Publicado: (2023)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Dynamics in COVID-19 symptoms during different waves of the pandemic among children infected with SARS-CoV-2 in the ambulatory setting
por: Ben-Tov, Amir, et al.
Publicado: (2022)

Immunogenicity trends 1 and 3 months after second BNT162B2 vaccination among healthcare workers in Israel
por: Shachor-Meyouhas, Yael, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021
por: Glatman-Freedman, Aharona, et al.
Publicado: (2021)

Acute myopericarditis following administration of the BNT162b2 booster vaccine against COVID19
por: Sivan, S.K., et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5–11 Years of Age, Israel
por: Glatman-Freedman, Aharona, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2ql86bnfm0ncarhg8mdfuh2k41